Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors Journal Article
| Authors: | Kondagunta, G. V.; Bacik, J.; Schwartz, L.; Sheinfeld, J.; Bajorin, D.; Vuky, J.; Marion, S.; Mazumdar, M.; Bosl, G. J.; Motzer, R. J. |
| Article Title: | Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors |
| Abstract: | Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients. |
| Keywords: | adult; clinical article; clinical trial; salvage therapy; cisplatin; advanced cancer; cancer combination chemotherapy; dose response; drug efficacy; side effect; solid tumor; temozolomide; neurotoxicity; carboplatin; dacarbazine; phase 2 clinical trial; etoposide; blood toxicity; antineoplastic activity; drug resistance, neoplasm; tumor marker; ifosfamide; confidence intervals; testicular neoplasms; malignant neoplastic disease; germ cell tumor; mediastinal neoplasms; phase ii; non seminomatous germinoma; nonseminoma; germinoma; teratocarcinoma; humans; human; male; female; priority journal; article; cisplatin-refractory |
| Journal Title: | Investigational New Drugs |
| Volume: | 22 |
| Issue: | 2 |
| ISSN: | 0167-6997 |
| Publisher: | Springer |
| Date Published: | 2004-04-01 |
| Start Page: | 177 |
| End Page: | 179 |
| Language: | English |
| DOI: | 10.1023/b:drug.0000011794.21608.59 |
| PROVIDER: | scopus |
| PUBMED: | 14739666 |
| DOI/URL: | |
| Notes: | Invest. New Drugs -- Cited By (since 1996):9 -- Export Date: 16 June 2014 -- CODEN: INNDD -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work